Bayer Enters Global License Agreement with Suzhou Puhe BioPharma for its PRMT5 Inhibitor
Shots:
- Bayer & Suzhou Puhe BioPharma have entered into a global license agreement for Puhe BioPharma’s PRMT5 inhibitor to treat MTAP-deleted tumors
- As per the deal, Bayer will obtain rights to develop, manufacture & commercialize MTA-cooperative PRMT5 inhibitor globally; financial terms remain undisclosed
- Bayer to develop the asset under development name BAY 3713372, with first pts enrollment reported in P-I dose escalation study for the treatment of MTAP-deleted solid tumors
Ref: Bayer | Image: Bayer & Suzhou Puhe BioPharma
Related News:- Bayer Reports the US FDA’s sNDA Acceptance & Priority Review of Finerenone for Heart Failure (HF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
